Shanghai RAAS Blood Products Co Ltd Class A Cash Flow Quality Index
Shanghai RAAS Blood Products Co Ltd Class A cash flow quality index. Shanghai RAAS Blood Products Co Ltd Class A (002252) has a Cash Flow Quality Index of -7.94x as of December 2025. Operating cash flow of CN¥-843.75 Million is below net income of CN¥106.27 Million, suggesting accrual-heavy earnings not yet converted to cash. See Shanghai RAAS Blood Products Co Ltd Clas free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Shanghai RAAS Blood Products Co Ltd Class A (2005–2025)
Cash flow quality index of Shanghai RAAS Blood Products Co Ltd Class A from 2005 to 2025. Historical Cash Flow Quality Index for Shanghai RAAS Blood Products Co Ltd Class A across 20 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore how well can Shanghai RAAS Blood Products Co Ltd Clas service its debt to assess how comfortably operating cash covers total debt obligations.
Shanghai RAAS Blood Products Co Ltd Class A Cash Flow Quality Index by Year (2005–2025)
Shanghai RAAS Blood Products Co Ltd Class A cash flow quality index by year from 2005 to 2025. Year-by-year earnings quality comparison for Shanghai RAAS Blood Products Co Ltd Class A. For the full cash flow conversion analysis, see 002252 cash flow metrics.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.07x | CN¥-104.89 Million | CN¥1.58 Billion | ▲ +69.7% |
| 2024 | -0.22x | CN¥-482.06 Million | CN¥2.19 Billion | ▼ -117.2% |
| 2023 | 1.28x | CN¥2.28 Billion | CN¥1.78 Billion | ▲ +38.9% |
| 2022 | 0.92x | CN¥1.73 Billion | CN¥1.87 Billion | ▼ -8.2% |
| 2021 | 1.00x | CN¥1.29 Billion | CN¥1.29 Billion | ▲ +13.3% |
| 2020 | 0.89x | CN¥1.17 Billion | CN¥1.32 Billion | ▼ -38.5% |
| 2019 | 1.44x | CN¥872.69 Million | CN¥605.92 Million | ▲ +345.8% |
| 2017 | 0.32x | CN¥268.76 Million | CN¥831.95 Million | ▼ -18.3% |
| 2016 | 0.40x | CN¥638.22 Million | CN¥1.61 Billion | ▼ -23.2% |
| 2015 | 0.52x | CN¥762.42 Million | CN¥1.48 Billion | ▼ -43.6% |
| 2014 | 0.91x | CN¥465.96 Million | CN¥510.51 Million | ▲ +244.4% |
| 2013 | -0.63x | CN¥-90.11 Million | CN¥142.52 Million | ▼ -153.7% |
| 2012 | 1.18x | CN¥263.46 Million | CN¥223.89 Million | ▲ +31.8% |
| 2011 | 0.89x | CN¥178.03 Million | CN¥199.45 Million | ▼ -17.3% |
| 2010 | 1.08x | CN¥200.21 Million | CN¥185.40 Million | ▲ +27.3% |
| 2009 | 0.85x | CN¥116.01 Million | CN¥136.77 Million | ▼ -17.1% |
| 2008 | 1.02x | CN¥107.64 Million | CN¥105.18 Million | ▼ -52.5% |
| 2007 | 2.15x | CN¥175.71 Million | CN¥81.63 Million | ▲ +103.7% |
| 2006 | 1.06x | CN¥53.58 Million | CN¥50.71 Million | ▲ +0.2% |
| 2005 | 1.05x | CN¥54.02 Million | CN¥51.24 Million | — |